The study population will consist of all subjects with a diagnosis of Parkinson's disease or a prescription for an antiparkinsonian drug who were registered for provincial medical services coverage or registered in a clinical practice (CPRD) at any time between January 1, 1990 (or 1 year after site-specific data is available, whichever is later) and June 30, 2012.